Product Details
Hemgenix
Etranacogene Dezaparvovec10,000,000,000,000 genome copies/mL
Suspension for Intravenous Infusion
Glass Vial
DIN/PIN/NPN
02542560
Manufacturer
CSL Behring Canada Inc.
Formulary Listing Date
2026-05-11
Unit Price
4,486,221.0000
Amount MOH Pays
4,486,221.0000
Coverage Status
Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
B02BD16
Interchangeable Products
NOLU Clinical Criteria
NORequirements
EAP Criteria
| Therapeutic Class | Reimbursement Criteria |
|---|---|
| Unclassified EAP Drugs | These drugs are not currently listed in the Exceptional Access Program Reimbursement Criteria for Frequently Requested Drugs – January 1, 2025 Edition Physicians may wish to contact the EAP directly by phone at 416-327-8109 or 1-866-811-9893 or by email at EAPFeedback.MOH@ontario.ca to see if an unlisted drug product and/or indication may be considered for EAP funding. |